版本:
中国

BRIEF-Advaxis says 38 pct of patients with heavily pretreated prmcc were alive 12 months following treatment with axalimogene filolisbac

March 15 Advaxis Inc

* Advaxis presents oral late-breaking data on phase 2 gog-0265 study of axalimogene filolisbac

* Advaxis - final efficacy results of gog-0265 demonstrated 38% of patients with heavily pretreated prmcc were alive 12 months following treatment with axalimogene filolisbac

* Advaxis inc - safety profile was consistent with previous clinical experience Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐